MWNA
NEOS

Marshall Wace North America’s Neos Therapeutics, Inc NEOS Stock Holding History

Marshall Wace North America’s Portfolio NEOS Stock Details NEOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-36,461
Closed -$228K – 1548
2018
Q2 		$228K Buy
+36,461
New +$272K ﹤0.01% 1241

Other funds holding NEOS

Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
LSC
Lyon Street Capital Sausalito, California $67M AUM
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return

Marshall Wace North America's NEOS Position: Q3 2018 in Review

Marshall Wace North America sold out of Neos Therapeutics, Inc (NEOS) in Q3 2018, closing a stake of 36,461 shares — an estimated $228K sold.

Marshall Wace North America first reported a position in NEOS in Q2 2018 and held it in 1 quarter. The position peaked at $228K in Q2 2018. 69 funds tracked by Wall St. Rank hold NEOS as of Q3 2018.

  • Marshall Wace North America reported no remaining Neos Therapeutics, Inc position as of Q3 2018 after selling out during the quarter.
  • Marshall Wace North America sold 36,461 Neos Therapeutics, Inc shares in Q3 2018, an estimated $228K.
  • Marshall Wace North America first reported a position in Neos Therapeutics, Inc in Q2 2018 and held it in 1 quarter.
  • Marshall Wace North America's Neos Therapeutics, Inc position peaked at $228K in Q2 2018.
  • 69 funds tracked by Wall St. Rank held Neos Therapeutics, Inc as of Q3 2018.

Based on Marshall Wace North America's 13F filing for Q3 2018, filed 14 Nov 2018.